Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity

Gallwitz, Baptist

dc.contributor.author	Gallwitz, Baptist
dc.date.accessioned	2023-05-23T09:16:04Z
dc.date.available	2023-05-23T09:16:04Z
dc.date.issued	2022
dc.identifier.issn	1664-2392
dc.identifier.uri	http://hdl.handle.net/10900/141344
dc.language.iso	en	de_DE
dc.publisher	Frontiers Media Sa	de_DE
dc.relation.uri	http://dx.doi.org/10.3389/fendo.2022.1004044	de_DE
dc.subject.ddc	610	de_DE
dc.title	Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity	de_DE
dc.type	Article	de_DE
utue.quellen.id	20230202000000_00883
utue.personen.roh	Gallwitz, Baptist
dcterms.isPartOf.ZSTitelID	Frontiers in Endocrinology	de_DE
dcterms.isPartOf.ZS-Issue	Article 1004044	de_DE
dcterms.isPartOf.ZS-Volume	13	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE